164 related articles for article (PubMed ID: 2540654)
1. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group Study).
Curry SL; Schlaerth JB; Kohorn EI; Boyce JB; Gore H; Twiggs LB; Blessing JA
Am J Obstet Gynecol; 1989 Apr; 160(4):805-9; discussion 809-11. PubMed ID: 2540654
[TBL] [Abstract][Full Text] [Related]
2. The influence of oral contraceptives on the postmolar human chorionic gonadotropin regression curve.
Morrow P; Nakamura R; Schlaerth J; Gaddis O; Eddy G
Am J Obstet Gynecol; 1985 Apr; 151(7):906-14. PubMed ID: 2580438
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives and postmolar trophoblastic disease.
Berkowitz RS; Goldstein DP; Marean AR; Bernstein M
Obstet Gynecol; 1981 Oct; 58(4):474-7. PubMed ID: 6269038
[TBL] [Abstract][Full Text] [Related]
4. Persistent gestational trophoblastic tumour with partial hydatidiform mole as the antecedent pregnancy.
Chen RJ; Huang SC; Chow SN; Hsieh CY; Hsu HC
Br J Obstet Gynaecol; 1994 Apr; 101(4):330-4. PubMed ID: 8199080
[TBL] [Abstract][Full Text] [Related]
5. Postmolar trophoblastic disease in women using hormonal contraception with and without estrogen.
Eddy GL; Schlaerth JB; Nalick RH; Gaddis O; Nakamura RM; Morrow CP
Obstet Gynecol; 1983 Dec; 62(6):736-40. PubMed ID: 6633999
[TBL] [Abstract][Full Text] [Related]
6. Identification of patients with persistent trophoblastic disease by means of a normal human chorionic gonadotropin regression curve.
Yedema KA; Verheijen RH; Kenemans P; Schijf CP; Borm GF; Segers MF; Thomas CM
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):787-92. PubMed ID: 7681253
[TBL] [Abstract][Full Text] [Related]
7. Uterine artery Doppler flow velocimetry parameters for predicting gestational trophoblastic neoplasia after complete hydatidiform mole, a prospective cohort study.
Asmar FTC; Braga-Neto AR; de Rezende-Filho J; Villas-Boas JMS; Charry RC; Maesta I
Clinics (Sao Paulo); 2017 May; 72(5):284-288. PubMed ID: 28591340
[TBL] [Abstract][Full Text] [Related]
8. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.
Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ
BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183
[TBL] [Abstract][Full Text] [Related]
9. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
[TBL] [Abstract][Full Text] [Related]
10. Relationship of oral contraception to development of trophoblastic tumour after evacuation of a hydatidiform mole.
Stone M; Dent J; Kardana A; Bagshawe KD
Br J Obstet Gynaecol; 1976 Dec; 83(12):913-6. PubMed ID: 188441
[TBL] [Abstract][Full Text] [Related]
11. Criteria toward the definition of nonmetastatic gestational trophoblastic disease after hydatidiform mole.
Kohorn EI
Am J Obstet Gynecol; 1982 Feb; 142(4):416-9. PubMed ID: 6277194
[TBL] [Abstract][Full Text] [Related]
12. The role of contraception in the development of postmolar gestational trophoblastic tumor.
Deicas RE; Miller DS; Rademaker AW; Lurain JR
Obstet Gynecol; 1991 Aug; 78(2):221-6. PubMed ID: 1648697
[TBL] [Abstract][Full Text] [Related]
13. Postmolar trophoblastic disease: diagnosis, management, and prognosis.
Morrow CP
Clin Obstet Gynecol; 1984 Mar; 27(1):211-20. PubMed ID: 6323079
[No Abstract] [Full Text] [Related]
14. Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?
Earp KE; Hancock BW; Short D; Harvey RA; Fisher RA; Drew D; Sarwar N; Tidy JA; Winter MC; Chien P; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():117-119. PubMed ID: 30684876
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of early-stage nonhydropic mole for diagnosis of persistent trophoblastic disease.
Miyoshi J; Ohba T; Fukunaga M; Katabuchi H
Obstet Gynecol; 2011 Oct; 118(4):847-53. PubMed ID: 21934448
[TBL] [Abstract][Full Text] [Related]
16. Gestational trophoblastic diseases - clinical guidelines for diagnosis, treatment, follow-up, and counselling.
Niemann I; Vejerslev LO; Frøding L; Blaakær J; Maroun LL; Hansen ES; Grove A; Lund H; Havsteen H; Sunde L
Dan Med J; 2015 Nov; 62(11):A5082. PubMed ID: 26522484
[TBL] [Abstract][Full Text] [Related]
17. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
[TBL] [Abstract][Full Text] [Related]
18. Partial hydatidiform mole with subsequent trophoblastic tumor; a case report.
Vejerslev LO; Larsen G; Jacobsen M
Eur J Obstet Gynecol Reprod Biol; 1991 Jun; 40(1):73-7. PubMed ID: 1649776
[TBL] [Abstract][Full Text] [Related]
19. Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study.
Kim BW; Cho H; Kim H; Nam EJ; Kim SW; Kim S; Kim YT; Kim JH
Eur J Obstet Gynecol Reprod Biol; 2012 Jan; 160(1):100-5. PubMed ID: 22055909
[TBL] [Abstract][Full Text] [Related]
20. Analysis of 309 cases after hydatidiform mole: different follow-up program according to biologic behavior.
Bolis G; Belloni C; Bonazzi C; Mangili G; Presti M; Zanaboni F; Mangioni C
Tumori; 1988 Feb; 74(1):93-6. PubMed ID: 2451334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
